Chronic allograft rejection (obliterative bronchiolitis)

Seminars in Respiratory and Critical Care Medicine

Volumn 22, Issue 5, 2001, Pages 551-557

  Verleden, G M ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Bronchiolitis obliterans syndrome; Chronic rejection; Obliterative bronchiolitis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 8;

AIRWAY OBSTRUCTION; BRONCHIOLITIS; BRONCHITIS; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; GRAFT REJECTION; HEART LUNG TRANSPLANTATION; HLA MATCHING; HUMAN; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0035184026     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18427     Document Type: Review

References (61)

1. The Registry of the International Society for Heart and Lung Transplantation: Seventeenth official report - 2000
2. A working formulation for the standardization of nomenclature for clinical staging of chronic dysfunction in lung allografts
3. Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation
4. Lung transplantation: A decade of experience
5. Incidence of obliterative bronchiolitis after heart-lung transplantation in children
6. The current status of lung transplantation
7. Bronchiolitis obliterans syndrome (BOS) following heart-lung transplantation
8. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation
9. Bronchial hyperreactivity after lung transplantation predicts early bronchiolitis obliterans
10. Primary pulmonary hypertension as a risk factor for the development of obliterative bronchiolitis in lung allograft recipients
11. Development of obliterative bronchiolitis after allogeneic lung transplantation: Implication of acute rejection and the time point of treatment
12. Obliterative bronchiolitis after lung and heart-lung transplantation: An analysis of risk factors and management
13. Analysis of risk factors for the development of bronchiolitis obliterans syndrome
14. "Refractoriness" of airflow obstruction associated with isolated lymphocytic bronchiolitis/bronchitis in pulmonary allografts
15. Bronchiolitis obliterans syndrome after lung transplantation: Medical treatment
16. Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3549 lung transplantations
17. Mismatches at the HLA-DR and HLA-B loci are risk factors for acute rejection after lung transplantation
18. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome
19. Risk factors for the development of obliterative bronchiolitis after lung transplantation
20. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients
21. Enhancement of obliterative airway disease in rat tracheal allografts infected with recombinant rat cytomegalovirus
22. Intermediate-term results after en bloc double-lung transplantation with bronchial arterial revascularisation
23. Medium term results of direct bronchial arterial revascularization using IMA for single lung transplantation (SLT) with direct revascularisation
24. Does bronchial artery revascularization influence results concerning bronchiolitis obliterans syndrome and/or obliterative bronchiolitis after lung transplantation?
25. Bronchial artery revascularization does not prevent bronchiolitis obliterans syndrome after lung transplantation
26. Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation
27. Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplantation
28. Endobronchial biopsy and bronchoalveolar lavage in stable lung transplant recipients and chronic rejection
29. Bronchiolitis obliterans syndrome after (heart)-lung transplantation: Impaired antiprotease defense and increased oxidant activity
30. Evidence for oxidative stress in bronchiolitis obliterans syndrome after lung and heart-lung transplantation
31. Immuno-histochemical localization of nitric oxide synthase and the oxidant peroxynitrite in lung transplant recipients with obliterative bronchiolitis
32. Expression of inducible nitric oxide synthase and formation of peroxynitrite in posttransplant obliterative bronchiolitis
33. The bronchial epithelium: A potential allogeneic target for chronic rejection after lung transplantation
34. Cyclosporine, FK506, mycophenolate mofetil, and prednisolone differentially modulate cytokine gene expression in human airway-derived epithelial cells
35. Immunopathologic changes in the airways of stable lung transplant recipients
36. Enhanced T cell cytokine gene expression in mouse airway obliterative bronchiolitis
37. Immune cells in a mouse airway model of obliterative bronchiolitis
38. Obliterative bronchiolitis after lung transplantation: A fibroproliferative disorder associated with platelet-derived growth factor
39. Measurement of fibroblast proliferative activity in bronchoalveolar lavage fluid in the analysis of obliterative bronchiolitis among lung transplant recipients
40. Up-regulation of inducible nitric oxide synthase in fibroblasts parallels the onset and progression of fibrosis in an experimental model of post-transplant obliterative airway disease
41. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome
42. Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: Proinflammatory role of bronchial epithelial cells
43. Immunohistochemical characterization of inflammatory and proliferative events during chronic rejection in rat lung allografts
44. Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation
45. Insulin-like growth factor-1 in lung transplants with obliterative bronchiolitis
46. Obliterative bronchiolitis after heart-lung transplantation: Apparent arrest by augmented immunosuppression
47. Bronchiolitis obliterans syndrome after lung transplantation and health-related quality of life
48. Obliterative bronchiolitis
49. Transbronchial biopsy in heart and lung transplantation: Clinico-pathologic correlations
50. The diagnosis of obliterative bronchiolitis after heart-lung and lung transplantation: Low yield of transbronchial biopsies
51. Physiologic definitions of obliterative bronchiolitis in heart-lung and double lung transplantation: A comparison of the forced expiratory flow between 25% and 75% of the forced vital capacity and forced expiratory volume in one second
52. Early detection of airway involvement in obliterative bronchiolitis after lung transplantation: Functional and bronchoalveolar lavage findings
53. High-resolution CT in long-term follow-up after lung transplantation
54. Detection of obliterative bronchiolitis after lung transplantation by indexes of ventilation distribution
55. Is there a role for measuring exhaled nitric oxide in lung transplant recipients with chronic rejection?
56. Cross-sectional study of exhaled nitric oxide levels following lung transplantation
57. Exhaled nitric oxide (eNO) and lung transplantation: Impact of the native lung?
58. Exhaled NO (eNO) after lung transplantation (LTx): A prospective study
59. Actuarial survival of heart-lung and bilateral lung transplant recipients with obliterative bronchiolitis
60. Obliterative bronchiolitis after lung and heart-lung transplantation